New treatment options against gram-negative organisms

Table 3 FDA status and pharmacokinetic characteristics of new carbapenems.

					Active against
Drug	FDA status	Dose	Administration	Half-life (h)	P. aeruginosa	MRSA	VRE	PRP
Ertapenem	Approved	1 g qd	i.v.	4	-	-	-	-
Doripenem	Approved	500 mg tid	i.v.	1	+	-	-	+
Biapenem	Phase II	300 mg bid	i.v.	1.03	+	-	-	+
Panipenem	Approved in Japan, China and Korea	0,5/0,5 g bid	i.v.	1.10-0.7	-	-	-	+
Tebipenem	Phase II	4 or 6 mg/kg bid	oral	U	-	-	U	+
Tomopenem	Phase II	700 mg	i.v.	1.7	+	+
Razupenem	Phase II	U	i.v.	U	+	+	+
Trinems		U	U	U	-	U	+/-	-

i.v.: intravenous; MRSA: methicillin-resistant S. aureus; PRP: penicillin-resistant pneumococci; U: unknown; VRE: vancomycin-resistant enterococci; +: active; -: non active; +/-: data only on small number of strains

ISSN: 1364-8535